<code id='6D06B6A1BD'></code><style id='6D06B6A1BD'></style>
    • <acronym id='6D06B6A1BD'></acronym>
      <center id='6D06B6A1BD'><center id='6D06B6A1BD'><tfoot id='6D06B6A1BD'></tfoot></center><abbr id='6D06B6A1BD'><dir id='6D06B6A1BD'><tfoot id='6D06B6A1BD'></tfoot><noframes id='6D06B6A1BD'>

    • <optgroup id='6D06B6A1BD'><strike id='6D06B6A1BD'><sup id='6D06B6A1BD'></sup></strike><code id='6D06B6A1BD'></code></optgroup>
        1. <b id='6D06B6A1BD'><label id='6D06B6A1BD'><select id='6D06B6A1BD'><dt id='6D06B6A1BD'><span id='6D06B6A1BD'></span></dt></select></label></b><u id='6D06B6A1BD'></u>
          <i id='6D06B6A1BD'><strike id='6D06B6A1BD'><tt id='6D06B6A1BD'><pre id='6D06B6A1BD'></pre></tt></strike></i>

          Home / entertainment / comprehensive

          comprehensive


          comprehensive

          author:leisure time    Page View:17598
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In